Management of bleeding emergencies: when to use recombinant activated Factor VII

Bibliography

• ALEDORT LM: Recombinant Factor VIIa is a pan-hemostatic agent? Thromb. Haemos. (2000) 83:637-638. Erratum in Thromb. Haemost. (2000) 84:523.
   PubMed Web of Science ®Google Scholar
• LEVI M, PETERS M, BULLER HR: Efficacy and safety of recombinant Factor VIIa for treatment of severe bleeding: a systematic review. Crit. Care Med. (2005) 33:883-890.
   PubMed Web of Science ®Google Scholar
• ENOMOTO TM, THORBORG P: Emerging off-label uses for recombinant activated factor VII: grading the evidence. Crit. Care Clin. (2005) 21(3):611-632.
   Google Scholar
• ABSHIRE T, KENET G: Recombinant Factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired Factor VII or IX inhibitors. J. Thromb. Haemost. (2004) 2:899-909.
   PubMed Web of Science ®Google Scholar
• CARR ME JR, MARTIN EJ: Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential. Expert Rev. Cardiovasc. Ther. (2004) 2:661-674.
   PubMedGoogle Scholar
• ROBERTS HR, MONROE DM, WHITE GC: The use of recombinant Factor VIIa in the treatment of bleeding disorders. Blood (2004) 104:3858-3864.
   PubMed Web of Science ®Google Scholar
• HEDNER U: Dosing with recombinant factor viia based on current evidence. Semin. Hematol. (2004) 41:35-39.
   PubMed Web of Science ®Google Scholar
• SHAPIRO AD, GILCHRIST GS, HOOTS WK, COOPER HA, GASTINEAU DA: Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb. Haemost. (1998) 80:773-778.
   PubMed Web of Science ®Google Scholar
• SEREMETIS S: Dose optimization of recombinant Factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. Blood Coagul. Fibrinolysis (2003) 14(Suppl. 1):S29-S30.
   Google Scholar
• WHITTEN CW, GREILICH PE: Thromboelastography: past, present, and future. Anesthesiology (2000) 92:1223-1225.
   PubMed Web of Science ®Google Scholar
• LISMAN T, DE GROOT PG: Mechanism of action of recombinant Factor VIIa. J. Thromb. Haemost. (2003) 1:1138-1139.
   PubMed Web of Science ®Google Scholar
• BUTENAS S, BRUMMEL KE, PARADIS SG, MANN KG: Influence of Factor VIIa and phospholipids on coagulation in ‘acquired’ hemophilia. Arterioscler. Thromb. Vasc. Biol. (2003) 23:123-129.
   PubMed Web of Science ®Google Scholar
• GABRIEL DA, LI X, MONROE DM III, ROBERTS HR: Recombinant human Factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J. Thromb. Haemost. (2004) 2:1816-1822.
   PubMed Web of Science ®Google Scholar
• LISMAN T, ADELMEIJER J, CAUWENBERGHS S, VAN PAMPUS EC, HEEMSKERK JW, DE GROOT PG: Recombinant Factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J. Thromb. Haemost. (2005) 3:742-751.
   PubMed Web of Science ®Google Scholar
• PORTE RJ, LEEBEEK FW: Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs (2002) 62:2193-2211.
   PubMed Web of Science ®Google Scholar
• KOVESI T, ROYSTON D: Pharmacological approaches to reducing allogeneic blood exposure. Vox Sang. (2003) 84:2-10.
   PubMed Web of Science ®Google Scholar
• BOLAN CD, ALVING BM: Pharacologic agents in the management of bleeding disorders. Transfusion (1990) 30:541-551.
   PubMed Web of Science ®Google Scholar
• CATTANEO M: Desmopressin in the treatment of patients with defects of platelet function. Haematologica (2002) 87:1122-1124.
   PubMed Web of Science ®Google Scholar
• BAUDUER F, BENDRISS P, FREYBURGER G, DUCOUT L, MARTI B: Use of desmopressin for prophylaxis of surgical bleeding in Factor XI-deficient patients. Acta Haematol. (1998) 99:52-53.
   PubMed Web of Science ®Google Scholar
• CASTAMAN G, RODEGHIERO F: Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time. Thromb. Res. (1993) 69:407-412.
   PubMed Web of Science ®Google Scholar
• FLORDAL PA: Use of desmopressin to prevent bleeding in surgery. Eur. J. Surg. (1998) 164:5-11.
   PubMedGoogle Scholar
• CATTANEO M, MANNUCCI PM: Desmopressin and blood loss after cardiac surgery. Lancet (1993) 342:812.
   PubMed Web of Science ®Google Scholar
• DUNN CJ, GOA KL: Tranexamic acid – a review of its use in surgery and other indications. Drugs (1999) 57:1005-1032.
   PubMed Web of Science ®Google Scholar
• ERSTAD BL: Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery. Ann. Pharmacother. (2001) 35:1075-1084.
   PubMed Web of Science ®Google Scholar
• AMITRANO L, GUARDASCIONE MA, BRANCACCIO V, BALZANO A: Coagulation disorders in liver disease. Semin. Liver Dis. (2002) 22:83-96.
   PubMed Web of Science ®Google Scholar
• Tranexamic acid. Med. Lett. Drugs Ther. (1987) 29:89-90.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ BS, WILLIAMS EC, CONLAN MG, MOSHER DF: Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor defiency. Ann. Intern. Med. (1986) 105:873-877.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, TATEWAKI W, WADA K, NIWANO H, SHIBATA A: Fibrinolysis and fibrinogenolysis in liver disease. Am. J. Hematol. (1990) 34:241-245.
   PubMed Web of Science ®Google Scholar
• SINDET-PEDERSEN S, RAMSTROM G, BERNVIL S, BLOMBACK M: Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N. Engl. J. Med. (1989) 320:840-843.
   PubMed Web of Science ®Google Scholar
• PORTE RJ, LEEBEEK FW: Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs (2002) 62:2193-2211.
   PubMed Web of Science ®Google Scholar
• JANSEN AJ, ANDREICA S, CLAEYS M, D’HAESE J, CAMU F, JOCHMANS K: Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br. J. Anaesth. (1999) 83:596-601.
   PubMed Web of Science ®Google Scholar
• CHAKRABARTI S, VARMA S, SINGH S, KUMARI S: Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia. Eur. J. Haematol. (1998) 60:313-314.
   PubMed Web of Science ®Google Scholar
• GAREWAL HS, DURIE BG: Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scand. J. Haematol. (1985) 35:497-500.
   PubMedGoogle Scholar
• WILSON RF, MAMMEN E, WALT AJ: Eight years of experience with massive blood transfusions. J. Trauma (1971) 11:275-285.
   PubMedGoogle Scholar
• HEDNER U, ERHARDTSEN E: Potential role for rFVIIa in transfusion medicine. Transfusion (2002) 42:114-124.
   PubMed Web of Science ®Google Scholar
• HAKALA P, HIIPPALA S, SYRJALA M, RANDELL T: Massive blood transfusion exceeding 50 units of plasma poor red cells or whole blood: the survival rate and the occurrence of leukopenia and acidosis. Injury (1999) 30:619-622.
   PubMed Web of Science ®Google Scholar
• CINAT ME, WALLACE WC, NASTANSKI F et al.: Improved survival following massive transfusion in patients who have undergone trauma. Arch. Surg. (1999) 134:964-968.
   PubMedGoogle Scholar
• DIMICHELE D, RIVARD G, HAY C, ANTUNES S: Inhibitors in haemophilia: clinical aspects. Haemophilia (2004) 10(Suppl. 4):140-145.
   PubMed Web of Science ®Google Scholar
• LLOYD JM, WIGHT J, PAISLEY S, KNIGHT C: Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. (2003) 9:464-520.
   PubMed Web of Science ®Google Scholar
• GALLISTL S, CVIRN G, MUNTEAN W: Recombinant Factor VIIa does not induce hypercoagulability in vitro. Thromb. Haemost. (1999) 81:245-249.
   PubMed Web of Science ®Google Scholar
• BECH RM: Recombinant Factor VIIa in joint and muscle bleeding episodes. Haemostasis (1996) 26 Suppl. 1:135-138.
   Google Scholar
• AHONEN J, JOKELA R: Recombinant Factor VIIa for life-threatening post-partum haemorrhage. Br. J Anaesth. (2005) 94:592-595.
   PubMed Web of Science ®Google Scholar
• LUSHER J, INGERSLEV J, ROBERTS H, HEDNER U: Clinical experience with recombinant Factor VIIa. Blood Coag. Fibrin. (1998) 9:119-128.
   PubMed Web of Science ®Google Scholar
• POON MC: Use of recombinant Factor VIIa in hereditary bleeding disorders. Curr. Opin. Hematol. (2001) 8:312-318.
   PubMed Web of Science ®Google Scholar
• DI PAOLA J, NUGENT D, YOUNG G: Current therapy for rare factor deficiencies. Haemophilia (2001) 7(Suppl. 1):16-22.
   PubMed Web of Science ®Google Scholar
• MATHIJSSEN NC, MASEREEUW R, VERBEEK K et al.: Prophylactic effect of recombinant Factor VIIa in Factor VII deficient patients. Br. J. Haematol. (2004) 125:494-499.
   PubMed Web of Science ®Google Scholar
• BOLTON-MAGGS PH: Factor XI deficiency and its management. Haemophilia (2000) 6(Suppl. 1):100-109.
   PubMed Web of Science ®Google Scholar
• BOLTON-MAGGS PHB, COLVIN BT, SATCHI G, LEE CA, LUCAS GS: Thrombogenic potential of Factor XI concentrate. Lancet (1994) 344:748-749.
   PubMed Web of Science ®Google Scholar
• O’CONNELL NM: Factor XI deficiency-from molecular genetics to clinical management. Blood Coagul. Fibrinolysis (2003) 14(Suppl. 1):S59-S64.
   Google Scholar
• BILLON S, LE NC, ESCOFFRE-BARBE M, VICARIOT M, ABGRALL JF: The use of recombinant Factor VIIa (NovoSeven) in a patient with a Factor XI deficiency and a circulating anticoagulant. Blood Coagul. Fibrinolysis (2001) 12:551-553.
   PubMed Web of Science ®Google Scholar
• LAWLER P, WHITE B, PYE S et al.: Successful use of recombinant Factor VIIa in a patient with inhibitor secondary to severe Factor XI deficiency. Haemophilia (2002) 8:145-148.
   PubMed Web of Science ®Google Scholar
• BAUDO F, DE CATALDO F, ITALIAN ASSOCIATION OF HAEMOPHILIA CENTRES (AICE): Acquired Factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG. (2003) 110:311-314.
   PubMed Web of Science ®Google Scholar
• BOGGIO LN, GREEN D: Acquired hemophilia. Rev. Clin. Exp. Hematol. (2001) 5:389-404.
   PubMedGoogle Scholar
• HEDNER U: Recombinant Factor VIIa (NovoSeven) as a hemostatic agent. Dis. Mon. (2003) 49:39-48.
   PubMed Web of Science ®Google Scholar
• DELOUGHERY TG: Coagulation defects in trauma patients: etiology, recognition, and therapy. Crit. Care Clin. (2004) 20:13-24.
   PubMed Web of Science ®Google Scholar
• SHAFFER LG, PHILLIPS MD: Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann. Int. Med. (1997) 127:206-209. Erratum in Ann. Intern. Med. (1998) 128:330.
   PubMed Web of Science ®Google Scholar
• WIESTNER A, CHO HJ, ASCH AS et al.: Rituximab in the treatment of acquired Factor VIII inhibitors. Blood (2002) 100:3426-3428.
   PubMed Web of Science ®Google Scholar
• ZETTERVALL O, NILSSON IM: Acquired von Willebrand’s disease caused by a monoclonal antibody. Acta Med. Scand (1978) 204:521.
   PubMed Web of Science ®Google Scholar
• TEFFERI A, NICHOLS WL: Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am. J. Med. (1997) 103:536-540.
   PubMed Web of Science ®Google Scholar
• JONGE POERINK-STOCKSCHLADER AB, DEKKER I, RISSEEUW-APPEL IM, HAHLEN K: Acquired Von Willebrand disease in children with a Wilms’ tumor. Med. Pediatr. Oncol. (1996) 26:238-243.
   PubMedGoogle Scholar
• ACHARYA S, BUSSEL JB: Hematologic toxicity of sodium valproate. J. Pediatr. Hematol. Oncol. (2000) 22:62-65.
   PubMed Web of Science ®Google Scholar
• LISMAN T, LEEBEEK FW, MEIJER K, VAN DER MJ, NIEUWENHUIS HK, DE GROOT PG: Recombinant Factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology (2002) 35:616-621.
   PubMed Web of Science ®Google Scholar
• VAN GENDEREN PJ, MICHIELS JJ: Acquired von Willebrand disease. Bail. Clin. Haem. (1998) 11:319-330.
   PubMedGoogle Scholar
• FEDERICI AB: Therapeutic approaches to acquired von Willebrand syndrome. Expert Opin. Investig. Drugs (2000) 9:347-354.
   PubMed Web of Science ®Google Scholar
• DELMER A, HORELLOU MH, BRÉCHOT JM et al.: Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins. Am. J. Hematol. (1992) 40:151-152.
   PubMed Web of Science ®Google Scholar
• FEDERICI AB, STABILE F, CASTAMAN G, CANCIANI MT, MANNUCCI PM: Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood (1998) 92:2707-2711.
   PubMed Web of Science ®Google Scholar
• FRIEDERICH PW, WEVER PC, BRIET E, DOORENBOS CJ, LEVI M: Successful treatment with recombinant Factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am. J. Hematol. (2001) 66:292-294.
   PubMed Web of Science ®Google Scholar
• MAJUMDAR G, PHILLIPS JK, LAVALLEE H, SAVIDGE GF: Acquired haemophilia in association with Type III von Willebrand’s disease: successful treatment with high purity von Willebrand’s factor and recombinant Factor VIIa. Blood Coagul. Fibrinolysis (1993) 4:1035-1037.
   PubMed Web of Science ®Google Scholar
• POON MC: Management of thrombocytopenic bleeding: is there a role for recombinant coagulation Factor VIIa. Curr. Hematol. Rep. (2003) 2:139-147.
   PubMedGoogle Scholar
• CAGLAR K, CETINKAYA A, AYTAC S, GUMRUK F, GURGEY A: Use of recombinant Factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr. Hematol. Oncol. (2003) 20:435-438.
   PubMed Web of Science ®Google Scholar
• VIDARSSON B, ONUNDARSON PT: Recombinant Factor VIIa for bleeding in refractory thrombocytopenia. Thromb. Haemost. (2000) 83:634-635.
   PubMed Web of Science ®Google Scholar
• POON MC, D’OIRON R, VON DM et al.: Prophylactic and therapeutic recombinant Factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J. Thromb. Haemost. (2004) 2:1096-1103.
   PubMed Web of Science ®Google Scholar
• ALMEIDA AM, KHAIR K, HANN I, LIESNER R: The use of recombinant Factor VIIa in children with inherited platelet function disorders. Br. J. Haematol. (2003) 121:477-481.
   PubMed Web of Science ®Google Scholar
• VIRCHIS A, HUGHES C, BERNEY S: Severe gastrointestinal haemorrhage responding to recombinant Factor VIIa in a Jehovah’s Witness with refractory immune thrombocytopenia. Hematol. J. (2004) 5:281-282.
   PubMedGoogle Scholar
• ERHARDTSEN E: Ongoing NovoSeven trials. Intensive Care Med. (2002) 28(Suppl. 2):S248-S255.
   Web of Science ®Google Scholar
• MAYER SA: Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke (2003) 34:224-229.
   PubMed Web of Science ®Google Scholar
• MAYER SA, BRUN NC, BRODERICK J et al.: Safety and feasibility of recombinant Factor VIIa for acute intracerebral hemorrhage. Stroke (2005) 36:74-79.
   PubMed Web of Science ®Google Scholar
• MAYER SA, BRUN NC, BEGTRUP K et al.: Recombinant activated Factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. (2005) 352:777-785.
   PubMed Web of Science ®Google Scholar
• DELOUGHERY TG: Management of bleeding with uremia and liver disease. Current. Opin. Hematol. (1999) 6:329-333.
   PubMedGoogle Scholar
• CARR JM: Hemostatic disorders in liver diease. In Disease of the Liver, 7th edn. Schiff L, Schiff ER (eds). J.B. Lippincott, Philadelphia (1993):1061-1076.
   Google Scholar
• KELLY DA, O’BRIEN FJ, HUTTON RA, TUDDENHAM EG, SUMMERFIELD JA, SHERLOCK S: The effect of liver disease on factors V, VIII and protein C. Br. J. Haematol. (1985) 61:541-548.
   PubMed Web of Science ®Google Scholar
• SPECTOR I, CORN M: Laboratory tests of hemostasis. The relation to hemorrhage in liver disease. Arch. Int. Med. (1967) 119:577-582.
   PubMedGoogle Scholar
• ELIZALDE JI, MOITINHO E, GARCIA-PAGAN JC et al.: Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. J. Hepatol. (1998) 29:789-795.
   PubMed Web of Science ®Google Scholar
• MEHTA AB, MCINTYRE N: Haematological disorders in liver disease. Forum (Genova) (1998) 8:8-25.
   PubMedGoogle Scholar
• HU KQ, YU AS, TIYYAGURA L, REDEKER AG, REYNOLDS TB: Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am. J. Gastroenterol. (2001) 96:1581-1586.
   PubMed Web of Science ®Google Scholar
• PALASCAK JE, MARTINEZ J: Dysfibrinogenemia associated with liver disease. J. Clin. Investig. (1977) 60:89-95.
   PubMed Web of Science ®Google Scholar
• MANNUCCI PM: Hemostatic drugs. N. Engl. J. Med. (1998) 339:245-253.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN DE, JEFFERS L, ERHARDTSEN E et al.: Recombinant Factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology (1997) 113:1930-1937.
   PubMed Web of Science ®Google Scholar
• SHAMI VM, CALDWELL SH, HESPENHEIDE EE, ARSENEAU KO, BICKSTON SJ, MACIK BG: Recombinant activated Factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transplantation (2003) 9:138-143.
   PubMed Web of Science ®Google Scholar
• EJLERSEN E, MELSEN T, INGERSLEV J, ANDREASEN RB, VILSTRUP H: Recombinant activated Factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand. J. Gastroenterol. (2001) 36:1081-1085.
   PubMed Web of Science ®Google Scholar
• ROMERO-CASTRO R, JIMENEZ-SAENZ M, PELLICER-BAUTISTA F et al.: Recombinant-activated Factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clin. Gastroenterol. Hepatol. (2004) 2:78-84.
   PubMed Web of Science ®Google Scholar
• BOSCH J, THABUT D, BENDTSEN F et al.: Recombinant Factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology (2004) 127:1123-1130.
   PubMed Web of Science ®Google Scholar
• VIGANO G, ZOJA C, CORNA D et al.: 17 beta-estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. J. Pharmacol. Exp. Ther. (1990) 252:344-348.
   PubMed Web of Science ®Google Scholar
• CARR JA, SILVERMAN N: The heparin-protamine interaction. A review. J. Cardiovasc. Surg. (1999) 40:659-666.
   PubMed Web of Science ®Google Scholar
• JASCHINSKI U, RIED M, LICHTWARCK-ASCHOFF M, FORST H: Bleeding diathesis due to failed antagonism of heparin: successful treatment with recombinant Factor VIIa. Anesth. Analg. (2004) 99:1872.
   PubMedGoogle Scholar
• HU Q, BRADY JO: Recombinant activated Factor VII for treatment of enoxaparin-induced bleeding. Mayo Clin. Proc. (2004) 79:827.
   PubMed Web of Science ®Google Scholar
• CHAN S, KONG M, MINNING DM, HEDNER U, MARDER VJ: Assessment of recombinant Factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J. Thromb. Haemost. (2003) 1:760-765.
   PubMed Web of Science ®Google Scholar
• BIJSTERVELD NR, MOONS AH, BOEKHOLDT SM et al.: Ability of recombinant Factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation (2002) 106:2550-2554.
   PubMed Web of Science ®Google Scholar
• LISMAN T, BIJSTERVELD NR, ADELMEIJER J et al.: Recombinant Factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J. Thromb. Haemost. (2003) 1:2368-2373.
   PubMed Web of Science ®Google Scholar
• A novel long-acting synthetic Factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J. Thromb. Haemost. (2004) 2:47-53.
   PubMed Web of Science ®Google Scholar
• PETITOU M, VAN BOECKEL CA: A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew. Chem. Int. Ed Engl. (2004) 43:3118-3133.
   PubMed Web of Science ®Google Scholar
• ELG M, CARLSSON S, GUSTAFSSON D: Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thromb. Res. (2001) 101:159-170.
   PubMed Web of Science ®Google Scholar
• DIEHL KH, ROMISCH J, HEIN B, JESSEL A, RONNEBERGER H, PAQUES EP: Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis (1995) 25:182-192.
   PubMedGoogle Scholar
• WOLZT M, LEVI M, SARICH TC et al.: Effect of recombinant Factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb. Haemost. (2004) 91:1090-1096.
   PubMed Web of Science ®Google Scholar
• ELG M, CARLSSON S, GUSTAFSSON D: Effect of activated prothrombin complex concentrate or recombinant Factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb. Res. (2001) 101:145-157.
   PubMed Web of Science ®Google Scholar
• BARTHELS M: Clinical efficacy of prothrombin complex concentrates and recombinant Factor VIIa in the treatment of bleeding episodes in patients with Factor VIII and IX inhibitors. Thromb. Res. (1999) 95:S31-S38.
   PubMedGoogle Scholar
• BERNTORP E: Recombinant FVIIa in the treatment of warfarin bleeding. Semin. Thromb. Hemost. (2000) 26:433-435.
   PubMed Web of Science ®Google Scholar
• KESSLER CM: Antidotes to haemorrhage: recombinant Factor VIIa. Best. Pract. Res. Clin. Haematol. (2004) 17:183-197.
   PubMed Web of Science ®Google Scholar
• DEVERAS RA, KESSLER CM: Reversal of warfarin-induced excessive anticoagulation with recombinant human Factor VIIa concentrate. Ann. Int. Med. (2002) 137:884-888.
   PubMed Web of Science ®Google Scholar
• FREEMAN WD, BROTT TG, BARRETT KM et al.: Recombinant Factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin. Proc. (2004) 79:1495-1500.
   PubMed Web of Science ®Google Scholar
• LIN J, HANIGAN WC, TARANTINO M, WANG J: The use of recombinant activated Factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J. Neurosurg. (2003) 98:737-740.
   PubMed Web of Science ®Google Scholar
• VESHCHEV I, ELRAN H, SALAME K: Recombinant coagulation Factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med. Sci. Monit. (2002) 8:CS98-CS100.
   PubMedGoogle Scholar
• BAKER RI, COUGHLIN PB, GALLUS AS, HARPER PL, SALEM HH, WOOD EM: Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med. J. Aust. (2004) 181:492-497.
   PubMed Web of Science ®Google Scholar
• KEY NS: Inhibitors in congenital coagulation disorders. Br. J. Haematol. (2004) 127:379-391.
   PubMed Web of Science ®Google Scholar
• FRIEDERICH PW, HENNY CP, MESSELINK EJ et al.: Effect of recombinant activated Factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet (2003) 361:201-205.
   PubMed Web of Science ®Google Scholar
• LODGE JP, JONAS S, OUSSOULTZOGLOU E et al.: Recombinant coagulation Factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology (2005) 102:269-275.
   PubMed Web of Science ®Google Scholar
• RAOBAIKADY R, REDMAN J, BALL JA, MALONEY G, GROUNDS RM: Use of activated recombinant coagulation Factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br. J. Anaesth. (2005) 94:586-591.
   PubMed Web of Science ®Google Scholar
• WOODMAN RC, HARKER LA: Bleeding complications associated with cardiopulmonary bypass. Blood (1990) 76:1680-1697.
   PubMed Web of Science ®Google Scholar
• BEVAN DH: Cardiac bypass haemostasis: putting blood throught the mill. Br. J. Haematol. (1999) 104:219.
   Google Scholar
• HALKOS ME, LEVY JH, CHEN E et al.: Early experience with activated recombinant Factor VII for intractable hemorrhage after cardiovascular surgery. Ann. Thorac. Surg. (2005) 79:1303-1306.
   PubMed Web of Science ®Google Scholar
• PYCHYNSKA-POKORSKA M, MOLL JJ, KRAJEWSKI W, JAROSIK P: The use of recombinant coagulation Factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr. Crit. Care Med. (2004) 5:246-250.
   PubMedGoogle Scholar
• RAIVIO P, SUOJARANTA-YLINEN R, KUITUNEN AH: Recombinant Factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann. Thorac. Surg. (2005) 80:66-71.
   PubMed Web of Science ®Google Scholar
• HYLLNER M, HOULTZ E, JEPPSSON A: Recombinant activated Factor VII in the management of life-threatening bleeding in cardiac surgery. Eur. J. Cardiothorac. Surg. (2005) 28:254-258.
   PubMed Web of Science ®Google Scholar
• KARKOUTI K, BEATTIE WS, WIJEYSUNDERA DN et al.: Recombinant Factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion (2005) 45:26-34.
   PubMed Web of Science ®Google Scholar
• DONICA SK, ROBERTS LC, DUKE PK et al.: Blood transfusion in orthotopic liver transplantation: six-year experience. Transplant. International (1992) 5(Suppl. 1):S214.
   PubMed Web of Science ®Google Scholar
• DZIK WH: Massive transfusion: lessons from liver transplantation. In: Massive Transfusion. Jefferies LC, Brecher ME (eds). American Association of Blood Banks, Bethesda, Maryland (1994):65-96.
   Google Scholar
• PARDO M, BARTOLOME J, CARRENO V, SANCHEZ J, QUEMADA FJ, DEL CA: Benefit of rFVIIa administration for cirrhotic patients undergoing surgery. World J. Surg. (2003) 27:758-759.
   PubMed Web of Science ®Google Scholar
• DE GASPERI A, BAUDO F, SCIASCIA A et al.: Recombinanat FVII in orthotopic liver transplantation: a way to reduce blood loss and transfusion requirements? Haematologica (2004) 88(Suppl. 6):77-78.
   Google Scholar
• PAVESE P, BONADONA A, BEAUBIEN J et al.: FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can. J. Anaesth. (2005) 52:26-29.
   PubMed Web of Science ®Google Scholar
• SURUDO T, WOJCICKI M, MILKIEWICZ P et al.: Rapid correction of prothrombin time after low-dose recombinant Factor VIIA in patients undergoing orthotopic liver transplantation. Transplant. Proc. (2003) 35:2323-2325.
   PubMed Web of Science ®Google Scholar
• HENDRIKS HG, MEIJER K, DE WOLF JT et al.: Reduced transfusion requirements by recombinant Factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation (2001) 71:402-405.
   PubMed Web of Science ®Google Scholar
• MARTINOWITZ U, MICHAELSON M: Guidelines for the use of recombianat activated Factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplanary rFVIIa task force. J. Thromb. Haemost. (2005) 3:640-648.
   PubMed Web of Science ®Google Scholar
• MARTINOWITZ U, KENET G, SEGAL E et al.: Recombinant activated Factor VII for adjunctive hemorrhage control in trauma. J. Trauma (2001) 51:431-438.
   PubMed Web of Science ®Google Scholar
• DUTTON RP, HESS JR, SCALEA TM: Recombinant Factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J. Clin. Anesth. (2003) 15:184-188.
   PubMed Web of Science ®Google Scholar
• STEIN DM, DUTTON RP: Uses of recombinant Factor VIIa in trauma. Curr. Opin. Crit Care (2004) 10:520-528.
   PubMedGoogle Scholar
• BOFFARD KD, RIOU B, WARREN B et al.: Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J. Trauma (2005) 59(1):8-15.
   Google Scholar
• MENG ZH, WOLBERG AS, MONROE DM III, HOFFMAN M: The effect of temperature and pH on the activity of Factor VIIa: implications for the efficacy of high-dose Factor VIIa in hypothermic and acidotic patients. J. Trauma (2003) 55:886-891.
   PubMedGoogle Scholar
• DANILOS J, GORAL A, PALUSZKIEWICZ P, PRZESMYCKI K, KOTARSKI J: Successful treatment with recombinant Factor VIIa for intractable bleeding at pelvic surgery. Obstet. Gynecol. (2003) 101:1172-1173.
   PubMed Web of Science ®Google Scholar
• HAAS T, INNERHOFER P, KUHBACHER G, FRIES D: Successful reversal of deleterious coagulopathy by recombinant Factor VIIa. Anesth. Analg. (2005) 100:54-58.
   PubMed Web of Science ®Google Scholar
• SCHUSTER R, LEE SJ, RINK D: Treatment of bleeding in severe hemorrhagic pancreatitis with recombinant Factor VIIa. Am. Surg. (2003) 69:1017-1018.
   PubMed Web of Science ®Google Scholar
• PARK P, FEWEL ME, THOMPSON BG, HOFF JT: Recombinant activated Factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery (2003) 53:34-38.
   PubMed Web of Science ®Google Scholar
• PASTORES SM, PAPADOPOULOS E, VOIGT L, HALPERN NA: Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant Factor VIIa. Chest (2003) 124:2400-2403.
   PubMed Web of Science ®Google Scholar
• GIELEN-WIJFFELS SE, VAN MOOK WN, VAN DER GS, RAMSAY G: Successful treatment of severe bleeding with recombinant Factor VIIa after kidney transplantation. Intensive Care Med. (2004) 30:1232-1234.
   PubMed Web of Science ®Google Scholar
• KARIMI M, ZAKERINIA M, KHOJASTEH HN, RAMZI M, AHMAD E: Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation. J. Thromb. Haemost. (2004) 2:1853-1855.
   PubMed Web of Science ®Google Scholar
• CLARK AD, GORDON WC, WALKER ID, TAIT RC: ‘Last-ditch’ use of recombinant Factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang. (2004) 86:120-124.
   PubMed Web of Science ®Google Scholar
• DESPOTIS G, AVIDAN M, LUBLIN DM: Off-label use of recombinant Factor VIIA concentrates after cardiac surgery. Ann. Thorac. Surg. (2005) 80:3-5.
   PubMed Web of Science ®Google Scholar
• RATKO TA, COMMINGS JP, MATUSZEWSKI KA: Off-label use of recombinant activated Factor VII (NovoSeven). P&T (2004) 29:712-720.
   Google Scholar